50 results about "Oral hypoglycemic agents" patented technology

A dispensing container which incorporates an aerosolizable topical insulin preparation, at least one oral hypoglycemic agent, and indicia and instructions for their coordinated use as a single therapeutic regimen for the treatment of diabetes mellitus in a human, and a method for treating diabetes mellitus which employs such a device.

This invention is directed to a pharmaceutical composition in the form of a tablet with improved stability, as well as the process for obtaining said composition. The tablet of the present invention comprises two active ingredients comprising two oral hypoglycemic agents: one phase with a sulphonylurea, such as immediate release Glimepiride, and a second phase with a biguanide, such as extended-release Metformin hydrochloride (Metformin HCl). The biphasic tablet, which can include over 500 mg of Metformin HCl (i.e. up to 1,000 or 1,500 mg, depending on the daily requirements of each patient), is to be orally administered once or twice a day. The combination of these hypoglycemic agents has a synergic effect and therefore a greater effectiveness in controlling the blood glucose level in patients with diabetes mellitus, type 2.

A method for treating postprandial hyperglycemia in diabetes mellitus in a human which employs a combination of an aerosolizable topical insulin and a short-acting oral hypoglycemic agent as a regimen taken adjacent to mealtime.

The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4 / 5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4 / 5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

Control of blood glucose is a fundamental goal in the treatment of diabetes mellitus. Glycation of l-lysine can lower blood glucose and advanced glycation end product (AGE) free adducts can be excreted in the urine. Lysine, an inexpensive amino acid, can be administered orally or parentally, and can be incorporated into a stereocomplex matrix as a time released preparation. In patients who suffer from diabetes and concomitant renal insufficiency who cannot clear sufficient quantities of AGE free adducts enantiomeric mixtures of lysine will lower blood glucose and AGEs since d-lysine has been shown to decrease protein glycation and lower hemoglobin Alc. This invention is not intended to replace insulin or oral hypoglycemic agents but is does offer patients a low cost and probably safe complementary therapy for the treatment of diabetes mellitus. In addition to the treatment of diabetes and its complications, this invention could lower AGE burden and slow or ameliorate some of the consequences of aging.

The Present invention relates to a process for the preparation of (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine of formula 1. (RS) 3-Methyl-1-(2-piperidinyl phenyl butyl amine having formula 1 is an important key intermediate for the synthesis of repaglinide of formula 2 an oral hypoglycemic agent.

The present invention discloses a composition preparation for preventing and treating diabetes, which mainly contains oral hypoglycemic agents, Vitamin E, chromic pyridine formate, selenium, lutein, folic acid, Vitamin C, alpha_lipoic acid, lycopene, nicotinamide, coenzyme Q10, and vitamin complexes and mineral. The medicament of the invention can decrease oxidative stress in vivo, promote body immunity, repair the critical organs in vivo such as pancreas, by supplying the mineral, vitamins and other substances which are insufficient in the patient suffering from diabetes, to prevent and treat diabetes.

The present invention provides a therapeutic agent for treatment of diabetes and hyperlipemia, especially a therapeutic agent for treatment of type II diabetes mellitus, which comprises as the active ingredient a neurotrophic factor such as BDNF (brain-derived neurotrophic factor), ligands of trkB or trkC receptors, NGF, NT-3, NT-4 / 5, CNTF, GDNF, HGF, etc. Different from conventional oral hypoglycemic agents being mainly used in the treatment of type II diabetes mellitus, the agent of the present invention exhibit blood lipid regulating effects and body fat accumulation regulating effects, in addition to the blood glucose regulating effects. Thus, the agent of the present invention are novel, and can reduce the risk factors in diabetes accompanied by hyperlipemia or obesity, without using any other agent.

It is intended to provide a pyrimidyl indoline compound which structurally differs from compounds used as active ingredients in conventional oral hypoglycemic agents and has excellent hypoglycemic effect. The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof:

A method of treating Type II diabetes utilizing two off-the-shelf drugs.Intravenous injection of one or both drugs, individually and in combination, can prevent and treat diabetes, restore damaged islet cell functions and reduce or stop the use of oral hypoglycemic agents and insulin.

The invention relates to the technical field of blood-sugar reducing healthcare products. The purpose of the invention is to provide a healthcare soft capsule with assistant blood-sugar reducing effect and a preparation method thereof, in order to solve the problems of drug dependence and occurrence of various complications caused by western-medicine control of diabetes treatment as well as side effects of oral blood-sugar reducing drugs which are commonly used in clinical treatment of diabetes. The healthcare soft capsule with assistant blood-sugar reducing effect is prepared from the following raw materials according to proportion: linseed oil, fagopyrum tataricum extract, American ginseng extract, chromium picolinate, beeswax, gelatin, glycerin, purified water, titanium dioxide, caramel color and so on. The preparation method comprises the following steps: preparing material solution of the soft capsule core, preparing glue solution of the soft capsule skin, preparing the soft capsules, shaping and drying the soft capsules, washing and drying the shaped soft capsules and selecting the prepared soft capsules, so that the healthcare soft capsules with assistant blood-sugar reducing effect are obtained. The healthcare soft capsule has scientific and rational production technology as well as stable and controllable quality, so that a safe, effective and reliable healthcare food is provided for the consumers. The healthcare soft capsule plays an important role in health care of Chinese residents, and has relatively high scientific values. Animal function and human trial tests have proven that the healthcare soft capsule has obvious assistant blood-sugar reducing effect.

The invention discloses a Chinese medical preparation assisting to adjusting blood sugar, relating to the field of traditional Chinese medicines. The medical preparation assisting to adjusting blood sugar is prepared from the following Chinese medical raw materials in percentage by weight: 1g of sealwort, 0.5-1.5g of polygonatum, 0.5-1.5g of salvia miltiorrhiza, 0.5-1.5g of radix astragali and 0.5-1.5g of fruit of glossy privet. Based on experiences for many years, the five Chinese medical herbs are proportionally prepared to effectively assist in adjusting the blood sugar of a patient, not only can the dosage of western medicines be reduced, but also complications caused by the microcirculatory disturbance of the patient can be improved. Proved by more than 30 clinical tests, the dosage of oral antidiabetic drugs in more than 80 percent of cases can be reduced by approximate one third to two thirds without toxic or side effect. The five Chinese medical herbs belong to pharmaceutical / food resources disclosed by the ministry of health, have reasonable prescription and low cost and are suitable for patients suffering from diabetes to use for a long time.

Diabetes consists of a worldwide public health concern that leads to high levels of morbidity and premature mortality and affects millions of people in countries of any level of development. It is estimated that there are more than 150 million people with diabetes in the world, wherein projections from the World Health Organization (WHO) for 2025 such amount may get to 300 million cases.The present invention refers to a process for obtaining an extract rich in rosmarinic acid (RA) from the plant Origanum vulgare and its use as a possible oral hypoglycemic agent for the treatment of diabetes.

The present invention relates to a natural medicine composition for preparing medicine capable of curing diabetes. Said medicine composition is formed from ganoderma and ang-kak according to a certain ratio. Said composition can be used as oral sugar-reducing medicine and food additive of health-care food, and can made into various oral dosage forms.

It is intended to provide a pyrimidyl indoline compound which structurally differs from compounds used as active ingredients in conventional oral hypoglycemic agents and has excellent hypoglycemic effect. The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof:

The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.

The Present invention relates to a process for the preparation of (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine of formula 1.(RS) 3-Methyl-1-(2-piperidinyl phenyl butyl amine having formula 1 is an important key intermediate for the synthesis of repaglinide of formula 2 an oral hypoglycemic agent.

The invention discloses a compound guava preparation and a manufacturing method thereof. The preparation is made from guava leaves, twigs of euonymus alatus, ficus hirta, mulberry leaves, kudzuvine roots, rhizoma coptidis, rhizoma atractylodis, rhizoma alismatis, hawthorn fruits and hongqu. The preparation has the efficacy of fortifying the spleen and resolving phlegm, reducing blood glucose and fat, and discharging the turbid and clearing heat, has an obvious effect on reduction of blood glucose, and can improve insulin resistance. In a clinical observation process, and in a compound guava preparation group, only three patients feel slight stomach discomfort and can self-relieve the discomfort without special treatment, and other patients have no untoward reaction. Therefore, the compound guava preparation is an efficient safe orally-administrated blood-glucose reducing medicine. The preparation is simple in formula and manufacturing method, convenient to consume, and suitable for industrial production and can be consumed for a long time.

A Chinese medicine for preventing and treating diabetes and its complications, and preventing arteriosclerosis and thrombosis is prepared from 6 Chinese-medicinal materials including mulberry leaf, gingko leaf, mulberry fruit, notoginseng, etc.

The invention relates to a tablet containing trelagliptin or trelagliptin succinate and a preparation method of the tablet, and belongs to the technical field of medicine preparations. The tablet can be singly used or jointly used together with other oral hypoglycemic agents, and is suitable for a patient with Type II diabetics. The tablet contains the trelagliptin or the trelagliptin succinate, a thinner, an adhesive, a disintegrant and a lubricant. The preparation method of the tablet containing the trelagliptin or the trelagliptin succinate comprises the following steps of (1) obtaining of medicine particles: uniformly mixing the trelagliptin or the trelagliptin succinate, the disintegrant and / or the thinner, adding a proper amount of adhesive, and granulating, so as to obtain the medicine particles; (2) obtaining of tabletting particles: uniformly mixing the medicine particles, the lubricant, the disintegrant and / or the thinner, so as to obtain the tabletting particles; (3) compression and forming: compressing and forming the tabletting particles by proper equipment. The tablet containing the trelagliptin or the trelagliptin succinate has the advantages that the dissolvability is good, the stability is good, the technology operation is simple and convenient, and the like; the technology is simple, the repeatability is good, and the tablet is especially suitable for industrial production.

The invention provides an oral hypoglycemic agent-voglibose tablet and a preparation method thereof. The composition of the tablet is calculated in parts by weight: 1 part of voglibose, 400-800 parts of filler, 30-150 parts of binder, 2-20 parts of lubricant and other components; Pass through the sieve respectively, then mix the sieved materials evenly, add a certain amount of binder to prepare a soft material, add lubricant after granulation and granulation, mix evenly, and press into tablets. The invention improves the stability of the voglibose tablet during storage, and better ensures the safety and effectiveness of medication for patients; at the same time, the preparation process is scientific and reasonable, simple and easy to operate, and has low production cost through production verification. features.

The present invention discloses a dripping pills preparation of thiazolidone oral hypoglycemic agent and its preparation method. Said dripping pills preparation is made up by using thiazolidone oral hypoglycemic agent, polyethylene glycol 6000, polyethylene 4000, poloxamer, stearic acid, tert-butyl-4-hydroxyphenyl methyl ether, sodium hydrogen sulfite, Tween-80 and carboxymethyl amylosodium.

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine foot soaping liquid for treating diabetes, and solves the problems that the traditional method for treating diabetes by orally taking drugs and injecting insulin has serious toxic side effect and bad curative effect and easily causes complicating disease and drug resistance. The liquid is composed of 14 drugs including leech, muskiness, chicken-bone herb, pericarpium zanthoxyli, red paeonia, mugwort leaf, radix aconiti, Guilu Erxian Jiao, prepared rhizome of rehmannia, Dioscorea opposita, cortex moutan, ginseng, polygonatum and the like. The drugs are soaked and then concentrated under normal pressure and concentrated under vacuum by a traditional Chinese medicine vacuum extracting machine set for extracting liquid medicines, and then the liquid medicine is made into a drug for external use preferably by a plenty of Chinese herbal medicines and by a special modern processing method in accordance with theory of traditional Chinese medicine. The drug is used in a foot soaking manner and a footherapy manner for treatment, and the drug has the functions, for human body, of soothing the liver and controlling breathing, promoting the production of body fluid to quench thirst, recovering glucose metabolism, balancing blood sugar, decreasing blood fat, promoting insulin secretion and keeping the blood sugar stable for a long time, and can enhance the immunity of the organism and avoid all defects of traditional oral drugs.

The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.

The invention discloses a market research method used for oral hypoglycemic agents. The method comprises the following steps that 1, a correlation information table of oral hypoglycemic agents on themarket is made; 2, sewage samples in a sewage treatment plant are collected, and refrigeration storage or heat preservation storage treatment is conducted on the sewage samples; 3, the collected sewage samples are subjected to separation and purification treatment, wherein by means of solid phase extraction, the sewage samples are subjected to separation and purification treatment; 4, different derivatization reagents are adopted for conducting derivatization reaction treatment on the sewage samples; 5, the sewage samples treated in the step 4 are subjected to samples analysis, liquid chromatography-mass spectrometry or gas chromatgraphy mass spectrometrometry is used for conducting qualitative and quantitative analysis, and then a consumption number per person, consumer group numbers, theprevalence rates and market shares of the oral hypoglycemic agents in the sewage samples are estimated; 6, data information obtained in the step 5 is analyzed, correlation parameters of the oral hypoglycemic agents are sorted out, and a market research report is drawn.

The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.

The present application relates to pharmaceutical compositions for reducing glucose excursions in a normal subject or a subject having an insulin-related disorder or dysglycemia. The pharmaceutical composition contains one or more active agent-containing layers, which each contain a dry blended mixture including a therapeutically effective amount of a polar ionizable insulin-sensitizing oral hypoglycemic agent or a pharmaceutically acceptable salt thereof, and an amphipathic compound in monomelic form consisting of an amphipathic ionic compound in monomelic form. Each dry blended mixture contains a sufficient amount of the amphipathic ionic compound such that upon contact with an aqueous fluid, the amphipathic ionic compound forms a reverse micelle comprising the polar ionizable insulin-sensitizing oral hypoglycemic agent. The present invention also relates to a use of a modified release pharmaceutical composition comprising a therapeutically effective amount of an insulin-sensitizing oral hypoglycemic agent for sensitizing pre-prandial (basal) insulin levels and / or reducing postprandial glucose excursions in a normal patient or a patient having an insulin-related disorder.